Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos Principais

A1362

Sigma-Aldrich

Agomelatine

≥98% (HPLC)

Sinônimo(s):

N-[2-(7-Methoxy-1-naphthalenyl)ethyl]-acetamide, S-20098

Faça loginpara ver os preços organizacionais e de contrato


About This Item

Fórmula empírica (Notação de Hill):
C15H17NO2
Número CAS:
Peso molecular:
243.30
Número MDL:
Código UNSPSC:
12352200
ID de substância PubChem:
NACRES:
NA.77
Preço e disponibilidade não estão disponíveis no momento.

Nível de qualidade

Ensaio

≥98% (HPLC)

Formulário

powder

cor

white to off-white

solubilidade

DMSO: >50 mg/mL

originador

Servier

temperatura de armazenamento

2-8°C

cadeia de caracteres SMILES

COc1ccc2cccc(CCNC(C)=O)c2c1

InChI

1S/C15H17NO2/c1-11(17)16-9-8-13-5-3-4-12-6-7-14(18-2)10-15(12)13/h3-7,10H,8-9H2,1-2H3,(H,16,17)

chave InChI

YJYPHIXNFHFHND-UHFFFAOYSA-N

Informações sobre genes

Aplicação

Agomelatine has been used:
  • to study its effects on adult neurogenesis and hippocampus apoptosis using the stress-induced depression model of rats[1]
  • to explore its effects on tau protein phosphorylation and to study its neuroprotective mechanism[2]
  • to study its effects on intracellular calcium ([Ca2+]i) signaling in peripheral neurons of rat dorsal root ganglion (DRG) neurons[3]

Ações bioquímicas/fisiológicas

Agomelatine is an extremely potent agonist at both melatonin receptors (MT1 and MT2), with additional antagonism at 5HT2C.
Agomelatine is an extremely potent agonist at both melatonin receptors (MT1 and MT2), with additional antagonism at 5HT2C. It is a novel antidepressant with many desired in vivo properties, including neuroprotection and neurogenesis in depression-sensitive brain areas. Agomelatine′s efficacy appears to be due to both melatonergic and serotonergic properties. In neurogenesis assays, both in vitro and in vivo, the compound effects were differentially affected by antagonists for MT1/MT2 and 5HT2C, demonstrating actions through all three receptors.
Agomelatine modulates the sleep-wake cycle through its chronobiotic activity. It normalizes the sleep pattern in patients suffering from depression and seasonal mood disorder.[1]

Características e benefícios

This compound is featured on the Melatonin Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Servier. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pictogramas

Environment

Palavra indicadora

Warning

Frases de perigo

Declarações de precaução

Classificações de perigo

Aquatic Acute 1 - Aquatic Chronic 1

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable


Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number

Não está vendo a versão correta?

Se precisar de uma versão específica, você pode procurar um certificado específico pelo número do lote ou da remessa.

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Os clientes também visualizaram

Slide 1 of 2

1 of 2

Melatonin receptor stimulation by agomelatine prevents Abeta-induced tau phosphorylation and oxidative damage in PC12 cells
Yao K, et al.
Drug design, development and therapy, 13, 387-387 (2019)
Two cases of delirium with agomelatine therapy.
María Gabriela Viejo Sacha et al.
Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, 25(1), 67-68 (2013-02-05)
Effect of agomelatine on adult hippocampus apoptosis and neurogenesis using the stress model of rats
Yucel A, et al.
Acta Histochemica, 118(3), 299-304 (2016)
Agomelatine modulates calcium signaling through protein kinase C and phospholipase C-mediated mechanisms in rat sensory neurons
Serhatlioglu I, et al.
Journal of Cellular Physiology, 234(7), 10741-10746 (2019)
V E Medvedev
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 112(5), 37-40 (2012-09-07)
According to data received from the study VREMYA, the combined therapy of moderate and severe non-psychotic depressions with Valdoxane and antidepressants of other pharmacological groups is effective and doesn't cause serious adverse events. These findings suggested using the indicated combination

Questions

Reviews

No rating value

Active Filters

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica